Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 21, 2026, 1:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 215 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Valproic Acid (VPA) Clear all
Recruiting Phase 1Phase 2 Interventional

Valproate for the Treatment of Residual Amblyopia

NCT07226141
View directory record Official record
Conditions
Amblyopia, Amblyopia Unilateral, Amblyopia, Anisometropic, Amblyopia Strabismic
Interventions
Valproate, Placebo, Patch
Drug · Behavioral
Lead sponsor
Boston Children's Hospital
Other
Eligibility
8 Years to 17 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2026 · Synced Sep 21, 2026, 1:43 PM EDT
Terminated Phase 4 Interventional Results available

Valproic Acid for Treatment of Hyperactive or Mixed Delirium in ICU

NCT02343575
View directory record Official record
Conditions
Hyperactive Delirium, Mixed Delirium
Interventions
Valproic Acid, Placebo, Haloperidol
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jun 25, 2019 · Synced Sep 21, 2026, 1:43 PM EDT
Completed Phase 1 Interventional

Valproic Acid in Treating Young Patients With Recurrent or Refractory Solid Tumors or CNS Tumors

NCT00107458
View directory record Official record
Conditions
Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions
valproic acid
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
2 Years to 21 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2012
U.S. locations
15
States / cities
Orange, California • Stanford, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Aug 6, 2014 · Synced Sep 21, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

Treatment of Mania Symptoms With Drug Therapy

NCT00183443
View directory record Official record
Conditions
Bipolar Disorder, Schizophrenia
Interventions
Divalproex-extended release (DVP-ER), Lithium, Quetiapine
Drug
Lead sponsor
Palo Alto Veterans Institute for Research
Other
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Palo Alto, California
Source: ClinicalTrials.gov public record
Updated Jul 16, 2018 · Synced Sep 21, 2026, 1:43 PM EDT
Completed Phase 2 Interventional

Pediatric Switch Study for Children and Adolescent Patients With Epilepsy

NCT00646711
View directory record Official record
Conditions
Pediatric Epilepsy
Interventions
Depakote Delayed-Release/Depakote Sprinkle, Depakote ER
Drug
Lead sponsor
Abbott
Industry
Eligibility
6 Years to 17 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 27, 2008 · Synced Sep 21, 2026, 1:43 PM EDT
Completed Not applicable Interventional

Comparison of Immediate vs Gradual Switch to Divalproex in Adults With Intellectual Disability

NCT00347152
View directory record Official record
Conditions
Epilepsy
Interventions
Divalproex
Drug
Lead sponsor
University of Kansas
Other
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Kansas City, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 11, 2008 · Synced Sep 21, 2026, 1:43 PM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Safety and Efficacy of Divalproex and Quetiapine in Elderly Alzheimer's Dementia Patients

NCT00375557
View directory record Official record
Conditions
Alzheimer's Disease, Dementia, Behavioral Symptoms
Interventions
Divalproex ER, Quetiapine
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
55 Years to 85 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2007
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 26, 2015 · Synced Sep 21, 2026, 1:43 PM EDT
Terminated Phase 4 Interventional Results available

Zidovudine, Interferon Alfa-2b, PEG-Interferon Alfa-2b in Patients With HTLV-I Associated Adult T-Cell Leukemia/Lymphoma

NCT00854581
View directory record Official record
Conditions
Lymphoma, Precancerous/Nonmalignant Condition
Interventions
PEG-interferon alfa-2b, Interferon alfa-2b, Valproic Acid, Zidovudine
Biological · Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Apr 16, 2018 · Synced Sep 21, 2026, 1:43 PM EDT
Terminated Phase 3 Interventional Results available

Efficacy and Safety of Ramelteon Sublingual in Adult Patients With Acute Depressive Episodes Associated With Bipolar I Disorder

NCT01467700
View directory record Official record
Conditions
Acute Depressive Episode
Interventions
Ramelteon SL, Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 75 Years
Enrollment
490 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
141
States / cities
Birmingham, Alabama • Dothan, Alabama • Muscle Shoals, Alabama + 137 more
Source: ClinicalTrials.gov public record
Updated May 15, 2016 · Synced Sep 21, 2026, 1:43 PM EDT
Completed Phase 4 Interventional

A Comparison of Two Standard Therapies in the Management of Dementia With Agitation

NCT00208819
View directory record Official record
Conditions
Senile Dementia, Alzheimer Type, Dementia, Alzheimer Type, Alzheimer Disease, Dementia
Interventions
risperidone, quetiapine, olanzapine, divalproex
Drug
Lead sponsor
Emory University
Other
Eligibility
65 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Nov 12, 2013 · Synced Sep 21, 2026, 1:43 PM EDT
Completed Phase 1 Interventional

Azacitidine and Valproic Acid Plus Carboplatin in Patients With Ovarian Cancer

NCT00529022
View directory record Official record
Conditions
Solid Tumors
Interventions
Azacitidine, Valproic Acid, Carboplatin
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 19, 2013 · Synced Sep 21, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional Results available

Study of Valproic Acid (VPA) vs Placebo to Shorten Time of Indwelling Pleural Catheter

NCT01900730
View directory record Official record
Conditions
Breast Cancer
Interventions
Placebo, Valproic Acid (VPA), Questionnaires, Pill Diary, Drainage Diary
Drug · Behavioral
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 24, 2020 · Synced Sep 21, 2026, 1:43 PM EDT
Not listed Phase 2 Interventional

Vidaza and Valproic Acid Post Allogeneic Transplant for High Risk AML and MDS

NCT02124174
View directory record Official record
Conditions
Acute Myelogenous Leukemia AML, Myelodysplastic Syndrome MDS
Interventions
Vidaza and Valproic Acid
Drug
Lead sponsor
Patrick Stiff
Other
Eligibility
2 Years to 89 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 25, 2021 · Synced Sep 21, 2026, 1:43 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Decision-Making in Bipolar Disorder

NCT01463111
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Lithium, Valproate, Lamotrigine
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2016
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated May 30, 2017 · Synced Sep 21, 2026, 1:43 PM EDT
Withdrawn Phase 4 Interventional

Safety Study of Depakote Versus Lithium in African Americans With Bipolar Disorder

NCT01075126
View directory record Official record
Conditions
Bipolar Disorder
Interventions
Depakote, Lithium
Drug
Lead sponsor
Lawson, William B., M.D., PhD, DFAPA
Individual
Eligibility
18 Years to 60 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 23, 2010 · Synced Sep 21, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Trial of Oral Valproic Acid for Retinitis Pigmentosa

NCT01233609
View directory record Official record
Conditions
Retinitis Pigmentosa
Interventions
Valproic Acid, Placebo
Drug
Lead sponsor
Foundation Fighting Blindness
Other
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
6
States / cities
Miami, Florida • Ann Arbor, Michigan • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 1, 2017 · Synced Sep 21, 2026, 1:43 PM EDT
Not listed Not applicable Interventional

Divalproex Sodium for Mood Swings and Alcohol Use Following Head Injury.

NCT01326663
View directory record Official record
Conditions
Veterans, TBI, Alcoholism, Irritable Mood
Interventions
Medication Trial
Drug
Lead sponsor
Paul Saenger
Other
Eligibility
18 Years to 65 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated Sep 6, 2012 · Synced Sep 21, 2026, 1:43 PM EDT
Completed Phase 3 Interventional Results available

This is an Open-label, Multi-center, Extension Study Designed to Evaluate the Longer Term Safety, Tolerability and Effectiveness of Lurasidone, Flexibly Dosed, Adjunctive to Lithium or Divalproex for the Treatment of Subjects With Bipolar I Disorder Who Have Participated in Study D1050296

NCT01575561
View directory record Official record
Conditions
Bipolar I Disorder
Interventions
Lurasidone
Drug
Lead sponsor
Sumitomo Pharma America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
377 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2015
U.S. locations
25
States / cities
Dothan, Alabama • Glendale, California • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Aug 21, 2016 · Synced Sep 21, 2026, 1:43 PM EDT
Terminated Phase 2 Interventional Results available

Valproic Acid and Dihydroergotamine as Abortive Therapy in Pediatric Migraine

NCT03885154
View directory record Official record
Conditions
Migraine in Children
Interventions
Valproic Acid (VPA), Dihydroergotamine (DHE)
Drug
Lead sponsor
Kimberly S Jones
Other
Eligibility
10 Years to 18 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Sep 21, 2026, 1:43 PM EDT
Active, not recruiting Phase 2 Interventional

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

NCT02068586
View directory record Official record
Conditions
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Stage I Intraocular Melanoma, Stage IIA Intraocular Melanoma, Stage IIB Intraocular Melanoma, Stage IIIA Intraocular Melanoma, Stage IIIB Intraocular Melanoma, Stage IIIC Intraocular Melanoma, Stage I Uveal Melanoma AJCC V7, Stage II Uveal Melanoma AJCC V7, Stage III Uveal Melanoma AJCC V7
Interventions
Sunitinib, Valproic Acid, Sunitinib Malate, Sunitinib Malate + Valproic Acid
Drug
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
210 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2026
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 15, 2026 · Synced Sep 21, 2026, 1:43 PM EDT
Completed Phase 2 Interventional Results available

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

NCT01817751
View directory record Official record
Conditions
Glioblastoma, Recurrent Adult Brain Neoplasm, Malignant Glioma, WHO Grade III Glioma
Interventions
sorafenib tosylate, valproic acid, sildenafil citrate
Drug
Lead sponsor
Virginia Commonwealth University
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2023
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Sep 21, 2026, 1:43 PM EDT
Not listed Phase 1 Interventional

Study of Depakote for Behavioral and Psychological Symptoms in Dementia

NCT00197834
View directory record Official record
Conditions
Dementia
Interventions
Depakote
Drug
Lead sponsor
Hearthstone Alzheimer Care
Industry
Eligibility
60 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2004
U.S. locations
1
States / cities
Hopkinton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 14, 2006 · Synced Sep 21, 2026, 1:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Divalproex Sodium Extended-Release Tablets 500 mg to Depakote ER® Tablets 500 mg

NCT00647712
View directory record Official record
Conditions
Healthy
Interventions
Divalproex Sodium Extended-Release Tablets 500 mg, Depakote ER® Tablets 500 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older · Male only
Enrollment
38 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2009 · Synced Sep 21, 2026, 1:43 PM EDT
Completed Phase 4 Interventional

Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder

NCT00203528
View directory record Official record
Conditions
Substance Abuse, Bipolar Depression
Interventions
divalproex sodium ER, risperidone
Drug
Lead sponsor
Tuscaloosa Research & Education Advancement Corporation
Other
Eligibility
19 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Tuscaloosa, Alabama
Source: ClinicalTrials.gov public record
Updated Mar 18, 2007 · Synced Sep 21, 2026, 1:43 PM EDT